REG - Oxford Biomedica PLC - Director/PDMR Shareholding

Oxford BioMedicaAnnouncement

03/05/2022 17:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220503:nRSC1724Ka&default-theme=true

RNS Number : 1724K  Oxford Biomedica PLC  03 May 2022

 

 

 

PDMR Dealings

 

Oxford, UK - 03 May 2022: Oxford Biomedica plc ("Oxford Biomedica" or "the
Company") (LSE: OXB), was informed on 03 May 2022, that Dr. Jason Slingsby,
Chief Business & Corporate Development Officer of the Group, exercised
8,712 LTIP (2018) options at nil cost on 27 April 2022, and sold all the
resulting ordinary shares at 539.0p per share. Following this transaction Dr.
Jason Slingsby continues to hold 120,476 options over ordinary shares.

 

The below notification, made in accordance with the requirements of the EU
Market Abuse Regulation, gives further detail of the number of Ordinary Shares
sold.

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Jason Slingsby
 2.  Reason for the notification
 a)  Position/status                          Chief Business & Corporate Development Officer

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford BioMedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Options over ordinary Shares of 50 pence each

     Identification code                      ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Exercise of options at nil cost
 c)  Currency                                 GBP - British pound
 d)  Price(s) and volumes(s)

Price(s)  Volume(s)
                                              Nil       8,712

 

 e)  Aggregated information

     -    Aggregate volume                    8,712

     -    Price

                                              Nil

     -    Aggregated total

                                              Nil
 f)  Date of the transaction                  2022-04-27
 g)  Place of the transaction                 Outside a trading venue

 

 

e)

Aggregated information

-    Aggregate volume

 

-    Price

 

-    Aggregated total

 

 

8,712

 

 

Nil

 

Nil

f)

Date of the transaction

2022-04-27

g)

Place of the transaction

Outside a trading venue

 

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Jason Slingsby
 2.  Reason for the notification
 a)  Position/status                          Chief Business & Corporate Development Officer

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford BioMedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code                      ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Disposal
 c)  Currency                                 GBP - British pound
 d)  Price(s) and volumes(s)

Price(s)  Volume(s)
                                              £5.39     8,712

 

 e)  Aggregated information

     -    Aggregate volume                    8,712

     -    Price

                                              £5.39

     -    Aggregated total

                                              £46,957.68
 f)  Date of the transaction                  2022-04-27
 g)  Place of the transaction                 London Stock Exchange, Main Market (XLON)

 

 

e)

Aggregated information

-    Aggregate volume

 

-    Price

 

-    Aggregated total

 

 

8,712

 

 

£5.39

 

£46,957.68

f)

Date of the transaction

2022-04-27

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 

-Ends-

 

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist
focused on delivering life changing therapies to patients.

 

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral
vector delivery systems including those based on lentivirus, adeno-associated
virus (AAV) and adenovirus, providing innovative solutions to cell and gene
therapy biotechnology and biopharma companies for their process development,
analytical development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector(®) platform,
which the Group leverages to develop product candidates in-house, before
seeking partners to take the products into clinical trials.

 

Oxford Biomedica is based across several locations and headquartered in
Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica
Solutions, a new US based subsidiary AAV manufacturing and innovation
business, based near Boston, US.

 

Oxford Biomedica employs more than 940 people. Further information is
available at www.oxb.com (https://www.oxb.com/)  .

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBUGDUDSGDGDX